Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100034/S041

Optune Gio - Maxpoint Version 2.0

Novocure, GmbH · Decision date Oct 23, 2025

FDA DECISIONP100034/S041

What did the FDA approve?

FDA records P100034/S041 as a supplement to PMA P100034, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 23, 2025.

FDA approval order statement

Approval for changes to the transducer array layout planning software MAXPOINT BR-I, including a trade name change to MAXPOINT.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Oct 23, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P100034/S041
Regulatory pathway
PMA supplement
Product code
NZK
Decision code
APPR
Decision date
Oct 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, low electric field, tumor treatment.

Product code
NZK
FDA device class
3

For the original device and its historical approval scope, see PMA P100034. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100034 · Original PMA

    NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT

  2. P100034/S041 received

    Application receipt date recorded by FDA.

  3. P100034/S041 · FDA decision

    Normal 180 Day Track

  4. P100034/S044 · Related supplement

    Optune HFE Transducer Array Soft Part Components

  5. P100034/S046 · Related supplement

    Optune HFE Transducer Arrays

  6. P100034/S045 · Related supplement

    Novocure GmbHs Optune Gio

Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100034

Product / regulatory recordCompanyPathwayDecision dateSource
Novocure, GmbHPMA approvalApr 8, 2011FDA
Optune GioP100034/S043
Novocure, GmbHPMA supplementFeb 25, 2026FDA
Novocure, GmbHPMA supplementApr 9, 2026FDA
Optune GioP100034/S042
Novocure, GmbHPMA supplementJun 4, 2026FDA
Novocure, GmbHPMA supplementSep 16, 2026FDA
Novocure, GmbHPMA supplementSep 18, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records